South Street Advisors LLC Acquires 58,350 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

South Street Advisors LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 229,765 shares of the biopharmaceutical company's stock after purchasing an additional 58,350 shares during the period. Halozyme Therapeutics accounts for about 1.7% of South Street Advisors LLC's holdings, making the stock its 28th biggest holding. South Street Advisors LLC owned approximately 0.18% of Halozyme Therapeutics worth $10,985,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in HALO. Raymond James Financial Inc. purchased a new position in Halozyme Therapeutics in the 4th quarter valued at about $21,838,000. Janney Montgomery Scott LLC boosted its position in Halozyme Therapeutics by 698.8% in the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after buying an additional 251,711 shares during the last quarter. Victory Capital Management Inc. boosted its position in Halozyme Therapeutics by 60.0% in the 4th quarter. Victory Capital Management Inc. now owns 650,751 shares of the biopharmaceutical company's stock valued at $31,112,000 after buying an additional 243,940 shares during the last quarter. Boston Trust Walden Corp boosted its position in Halozyme Therapeutics by 28.0% in the 4th quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after buying an additional 191,465 shares during the last quarter. Finally, Hantz Financial Services Inc. purchased a new position in Halozyme Therapeutics in the 3rd quarter valued at about $9,260,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Halozyme Therapeutics Stock Performance

HALO traded up $0.84 on Friday, hitting $65.16. 4,001,023 shares of the company's stock were exchanged, compared to its average volume of 1,327,557. The firm has a market cap of $8.02 billion, a PE ratio of 19.00, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53. The stock has a fifty day moving average of $58.20 and a two-hundred day moving average of $54.76. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HALO. Benchmark restated a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler upped their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $62.78.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares of the company's stock, valued at approximately $1,972,629.59. This trade represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,697 shares of company stock worth $1,754,451 over the last three months. Corporate insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.